marked.bio

FAK inhibitor · small molecule

ifebemtinib

7 active trials across 3 of our biomarkers, targeting FAK. Not approved for any biomarker on marked.bio yet.

Also known as IN10018, BI 853520.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
KRAS G12C 5 5 Phase 3
EGFR exon 19 deletion / L858R 1 1 Phase 1/2
KRAS G12D 1 1 Phase 1/2

Sponsors

Industry sponsors leading active biomarker-selected trials of ifebemtinib.

  1. InxMed 4
  2. Shanghai Jeyou Pharmaceutical 1
  3. InventisBio 1
  4. Jemincare 1

Trials

7 of 7 trials shown

  1. A Phase 3 Study of Sosimerasib in Combination With IN10018 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation

    Not yet recruiting Phase 3 Shanghai Jeyou Pharmaceutical Started 2026Primary completion 2029-04 NCT07833202

    ifebemtinibtislelizumabcarboplatinpemetrexed

    Has KRAS G12C mutation confirmed by central laboratory.

    KRAS G12CNSCLC

  2. A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation

    Recruiting Phase 3 InxMed Started 2025Primary completion 2028-09 NCT07174908

    ifebemtinibgarsorasibpemetrexed

    Has KRAS G12C mutation confirmed by central laboratory

    KRAS G12CNon-Small Cell Lung Cancer

  3. IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors

    Recruiting Phase 1/2 InxMed Started 2026Primary completion 2031-02 NCT07441174

    ifebemtinib

    Subjects confirmed to be KRASG12D mutation-positive in tumor tissue samples.

    KRAS G12DSolid Tumor Cancer, PDAC

  4. IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC

    Recruiting Phase 1/2 InxMed Started 2023Primary completion 2026-07 NCT05994131

    ifebemtinibfurmonertinib

    Documented EGFR mutations known to be associated with EGFR-TKI sensitivity, including Ex19del or L858R.

    EGFR exon 19 deletion / L858RNSCLC

  5. Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors

    Active, not recruiting Phase 1/2 InventisBio Started 2022Primary completion 2027-12 NCT05379946

    garsorasibifebemtinib

    Subject has KRasG12C mutation in tumor tissue or other biospecimens (only for phase1b) containing cancer cells…

    KRAS G12CSolid Tumor

  6. a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors

    Active, not recruiting Phase 1/2 InxMed Started 2022Primary completion 2027-12 NCT06166836

    garsorasibifebemtinib

    Confirmed positive KRAS G12C mutation in tumor tissue or other biospecimens (only for phase1b) containing cancer cells…

    KRAS G12CSolid Tumor

  7. A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation

    Recruiting Phase 1 Jemincare Started 2025Primary completion 2026-02 NCT06946927

    JMKX001899ifebemtinibpemetrexedcarboplatin

    Known KRAS G12C mutation, and negative results for other driver genes with approved targeted therapies.

    KRAS G12CNSCLC (Advanced Non-small Cell Lung Cancer)